MiR‐381 targets LRRC‐4, thereby suppressing the expression of bromodomain‐containing protein 7 (BRD7), a transcriptional cofactor for the tumour suppressor gene p53, and promoting cell proliferation in glioma. Here, BRD7 is linked to central nervous system cancer.